Astellas may buy mitochondria start-up Mitokyne as part of R&D alliance
This article was originally published in Scrip
Astellas's new research partnership with the private US venture Mitokyne is in line with the Japanese firm's revised R&D strategy, under which it is making more use of external expertise and moving into new therapeutic areas.
You may also be interested in...
Astellas builds on a 2013 collaboration by acquiring Mitobridge. Ardelyx is partnering with Kyowa Hakko Kirin to bring tenapanor to market in Japan. Meanwhile, Depomed, Xoma and Bristol all offload programs before the end of the year.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.